Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari "Aldo Moro" , Bari , Italy and.
Arch Physiol Biochem. 2013 Oct;119(4):139-50. doi: 10.3109/13813455.2013.796996. Epub 2013 May 31.
The close link between type 2 diabetes and excess body weight highlights the need to consider the effects on weight of different treatments used for correction of hyperglycaemia. Indeed, specific currently available diabetes therapies can cause weight gain, including insulin and its analogues, sulphonylureas, and thiazolidinediones, while others, such as metformin and the GLP-1 receptor agonists, can promote weight loss. Excess body weight in patients with diabetes is largely due to expansion of adipose tissue, and these drugs could interfere with the mechanisms underlying the expansion and differentiation of adipocyte precursors. Almost all anti-diabetes drugs could also potentially affect adipocyte metabolism directly, by modulating lipogenesis, lipolysis, and fat oxidation. This review will examine the available evidence for specific effects of various anti-diabetes drugs on adipose tissue development and function with the ultimate goal of increasing our understanding of how pharmacological agents can modulate energy balance and body fat.
2 型糖尿病与超重之间的密切关系突出表明，需要考虑不同用于纠正高血糖的治疗方法对体重的影响。事实上，目前可用的一些特定糖尿病疗法会导致体重增加，包括胰岛素及其类似物、磺酰脲类药物和噻唑烷二酮类药物，而其他一些药物，如二甲双胍和 GLP-1 受体激动剂，则可以促进体重减轻。糖尿病患者的超重主要是由于脂肪组织的扩张，这些药物可能会干扰脂肪细胞前体扩张和分化的机制。几乎所有的抗糖尿病药物也可能通过调节脂肪生成、脂肪分解和脂肪氧化，直接影响脂肪细胞代谢。这篇综述将检查各种抗糖尿病药物对脂肪组织发育和功能的具体作用的现有证据，最终目的是增加我们对药理制剂如何调节能量平衡和体脂肪的理解。
